Cannabinoid · Phytocannabinoid
Cannabielsoin (CBE) is a phytocannabinoid made by the cannabis plant, in the CBE-type group. An oxidation product of CBD.
Where it fits
Cannabielsoin (CBE) derives from CBD (oxidation). See the Phytocannabinoids index for how it relates to the rest of the family.
What the research shows
Direct human research on Cannabielsoin (CBE) is minimal; it is characterised mainly by its chemistry and its place in the cannabinoid family rather than by clinical studies. We flag that plainly rather than overstate it.
FAQ
Is CBE intoxicating? No. Cannabielsoin (CBE) is non-intoxicating.
Where does CBE come from? From CBD (oxidation).
Is CBE also formed as a metabolite of CBD in the body? Yes. Hepatic cytochrome P450 enzymes convert CBD into a 1S,2R-epoxy-CBD intermediate that cyclizes into cannabielsoin (CBE).
Photo-Oxidative CBD Epoxidation, CBEA Decarboxylation, and Hepatic CYP450 Metabolism
Cannabielsoin (CBE, C21H30O3) is a tricyclic dihydrobenzofuran phytocannabinoid formed either via photo-oxidation of CBDA into cannabielsoic acids (CBEA-A and CBEA-B) followed by thermal decarboxylation (Shoyama et al., 1972, PubMed PMID 4647625; Uliss et al., 1974, PubMed PMID 4425269) or as a mammalian hepatic cytochrome P450 metabolite of CBD via 1S,2R-epoxy-CBD intermediate cyclization (Yamamoto et al., 1991, PubMed PMID 1806944). In vivo mammalian pharmacology studies show that CBE does not produce THC-like catalepsy and mildly reduces pentobarbital-induced hypothermia (Yamamoto et al., 1991, PubMed PMID 1806944).
Part of the NOIDS cannabinoids index. Educational reference, not medical advice.